Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report
The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleuk...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2019/8607657 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567341830897664 |
|---|---|
| author | Virginija Kalinauskaite-Zukauske Andrius Januskevicius Ieva Janulaityte Skaidrius Miliauskas Kestutis Malakauskas |
| author_facet | Virginija Kalinauskaite-Zukauske Andrius Januskevicius Ieva Janulaityte Skaidrius Miliauskas Kestutis Malakauskas |
| author_sort | Virginija Kalinauskaite-Zukauske |
| collection | DOAJ |
| description | The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 109/l to 0.14 ± 0.04 × 109/l (p=0.01) and FEV1 increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) (p=0.04), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL (p=0.02) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL (p=0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level (r = 0.81, p=0.008), as well as between changes in serum IL-25 and TSLP levels (r = 0.93, p=0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359. |
| format | Article |
| id | doaj-art-de30026aa5b641e1bea2412d04b0722e |
| institution | Kabale University |
| issn | 1198-2241 1916-7245 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-de30026aa5b641e1bea2412d04b0722e2025-02-03T01:01:47ZengWileyCanadian Respiratory Journal1198-22411916-72452019-01-01201910.1155/2019/86076578607657Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short ReportVirginija Kalinauskaite-Zukauske0Andrius Januskevicius1Ieva Janulaityte2Skaidrius Miliauskas3Kestutis Malakauskas4Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, LT-50161, LithuaniaLaboratory of Pulmonology, Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, LT-50161, LithuaniaLaboratory of Pulmonology, Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, LT-50161, LithuaniaDepartment of Pulmonology, Lithuanian University of Health Sciences, Kaunas, LT-50161, LithuaniaDepartment of Pulmonology, Lithuanian University of Health Sciences, Kaunas, LT-50161, LithuaniaThe bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 109/l to 0.14 ± 0.04 × 109/l (p=0.01) and FEV1 increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) (p=0.04), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL (p=0.02) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL (p=0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level (r = 0.81, p=0.008), as well as between changes in serum IL-25 and TSLP levels (r = 0.93, p=0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359.http://dx.doi.org/10.1155/2019/8607657 |
| spellingShingle | Virginija Kalinauskaite-Zukauske Andrius Januskevicius Ieva Janulaityte Skaidrius Miliauskas Kestutis Malakauskas Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report Canadian Respiratory Journal |
| title | Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report |
| title_full | Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report |
| title_fullStr | Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report |
| title_full_unstemmed | Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report |
| title_short | Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report |
| title_sort | serum levels of epithelial derived cytokines as interleukin 25 and thymic stromal lymphopoietin after a single dose of mepolizumab in patients with severe non allergic eosinophilic asthma a short report |
| url | http://dx.doi.org/10.1155/2019/8607657 |
| work_keys_str_mv | AT virginijakalinauskaitezukauske serumlevelsofepithelialderivedcytokinesasinterleukin25andthymicstromallymphopoietinafterasingledoseofmepolizumabinpatientswithseverenonallergiceosinophilicasthmaashortreport AT andriusjanuskevicius serumlevelsofepithelialderivedcytokinesasinterleukin25andthymicstromallymphopoietinafterasingledoseofmepolizumabinpatientswithseverenonallergiceosinophilicasthmaashortreport AT ievajanulaityte serumlevelsofepithelialderivedcytokinesasinterleukin25andthymicstromallymphopoietinafterasingledoseofmepolizumabinpatientswithseverenonallergiceosinophilicasthmaashortreport AT skaidriusmiliauskas serumlevelsofepithelialderivedcytokinesasinterleukin25andthymicstromallymphopoietinafterasingledoseofmepolizumabinpatientswithseverenonallergiceosinophilicasthmaashortreport AT kestutismalakauskas serumlevelsofepithelialderivedcytokinesasinterleukin25andthymicstromallymphopoietinafterasingledoseofmepolizumabinpatientswithseverenonallergiceosinophilicasthmaashortreport |